Wilms Tumour Africa
Where We Work Worldwide
Wilms Tumour Africa collaboration
A multi-disciplinary group of experts in sub-Saharan Africa have formed a collaboration to implement a locally adapted treatment protocol to implement best practice in treating this kidney tumour.

4 Countries

involved in the African collaboration

7 Centres

involved in the collaboration across the 5 countries

Programme Information


Malawi, Cameroon (3 centres), Ghana (2 centres) and Zimbabwe


Princess Maxima Centre for Pediatric Oncology, Netherlands


Prof Lorna Renner & Dr Vivian Paintsil – Ghana, Prof Elizabeth Molyneux & Dr George Chagaluka – Malawi, Dr Francine Kouya – Cameroon, Dr Inam Chitsike – Zimbabwe


Dr Trijn Israels, Princess Maxima Centre

Start Date

March 2014


Survival from childhood cancer in sub-Saharan Africa is possible and twinning partnerships in the region have produced considerable progress. Wilms’ tumour is a relatively common and treatable kidney tumour, with survival rates of around 85% in developed countries.

 Treatment is multi-disciplinary and includes the involvement of paediatricians, surgeons, nurses, radiologists and pathologists to name a few. A multi-disciplinary group of African clinicians and international experts produced a consensus treatment guideline adapted to local circumstances with emphasis on social support to enable parents to complete treatment and provision of adequate supportive care.

This guideline is now being used to treat children with Wilms’ tumour across several African centres, and the outcomes are monitored closely in order to understand the effectiveness of this treatment.

Key Activities

Seven centres across four countries involved in the collaboration Consensus treatment guideline produced Nutritional assessment and support Assistance with treatment and travel costs Regional training to build diagnosis capacity Central data collection and dissemination of progress Regular meetings and mentoring for teams Support for families through treatment Follow-up patients after completion of treatment


Limited access to diagnosis and treatment

Historical lack of a consensus treatment guideline

Little support for patients for drugs, transport and food

Families abandon treatment due to lack of social support

Inaccurate and delayed diagnosis

Little opportunity for collaboration and knowledge exchange

Lack of data collection systems or management

Will you join us?

Together we can close the gap in childhood cancer care.


Our History

Our People

Work for Us

Annual Reviews & Accounts